+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Global Cardiovascular Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5410400
The Global Cardiovascular Drugs Market is estimated to be USD 87.29 Bn in 2023 and is expected to reach USD 117.98 Bn by 2028 growing at a CAGR of 6.21%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Cardiovascular Drugs Market is segmented based on Type, Drugs, Disease Indications, Route of Administration, Mode of Purchase, Distribution Channel, and Geography.
  • By Type, the market is classified into Antihyperlipidemic, Antihypertensives, Anticoagulants, Antiarrhythmics, and Others.
  • By Drugs, the market is classified into Branded Drugs and Generic Drugs.
  • By Disease Indications, the market is classified into Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, and Others.
  • By Route of Administration, the market is classified into Oral, Parenteral, and Others.
  • By Mode of Purchase, the market is classified into Prescription-Based Drugs and Over-The-Counter Drugs.
  • By Distribution Channel, the market is classified into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others.
  • By Geography, the market is classified into Americas, Europe, Middle East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Bristol Myers Squibb Co., Pfizer, Novartis Ag, Abbott Laboratories etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Cardiovascular Drugs Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Cardiovascular Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Cardiovascular Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 and the impact of economic slowdown & impending recession on the market are also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Rise in Number of Cardiovascular Disease
4.1.2 Increasing Geriatric Population
4.1.3 Existence of Numerous Novel Drugs
4.2 Restraints
4.2.1 Stringent Regulations for Development of New Drugs
4.3 Opportunities
4.3.1 Advancement in R&D for Effective Drugs
4.3.2 Rising Healthcare Expenditure in Emerging Countries
4.4 Challenges
4.4.1 Patent Expiry of Various Blockbuster Drugs
4.4.2 Side-Effects of Cardiovascular Drugs
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTEL Analysis
5.4 SWOT Analysis
5.5 Impact of Covid-19
5.6 Impact of Economic Slowdown & Impending Recession
5.7 Ansoff Matrix Analysis
6 Global Cardiovascular Drugs Market, By Type
6.1 Introduction
6.2 Antihypertensive
6.3 Antihyperlipidemic
6.4 Anticoagulants
6.5 Antiplatelet Drugs
6.6 Others
7 Global Cardiovascular Drugs Market, By Drugs
7.1 Introduction
7.2 Branded Drugs
7.3 Generic Drugs
8 Global Cardiovascular Drugs Market, By Disease Indications
8.1 Introduction
8.2 Hypertension
8.3 Hyperlipidaemia
8.4 Coronary Artery Disease
8.5 Arrhythmia
8.6 Others
9 Global Cardiovascular Drugs Market, By Route of Administration
9.1 Introduction
9.2 Oral
9.3 Parenteral
9.4 Others
10 Global Cardiovascular Drugs Market, By Mode of Purchase
10.1 Introduction
10.2 Prescription-Based Drugs
10.3 Over-the-Counter Drugs
11 Global Cardiovascular Drugs Market, By Distribution Channel
11.1 Introduction
11.2 Hospital Pharmacies
11.3 Retail Pharmacies
11.4 Online Pharmacies
11.5 Others
12 Americas' Cardiovascular Drugs Market
12.1 Introduction
12.2 Argentina
12.3 Brazil
12.4 Canada
12.5 Chile
12.6 Colombia
12.7 Mexico
12.8 Peru
12.9 United States
12.10 Rest of Americas
13 Europe's Cardiovascular Drugs Market
13.1 Introduction
13.2 Austria
13.3 Belgium
13.4 Denmark
13.5 Finland
13.6 France
13.7 Germany
13.8 Italy
13.9 Netherlands
13.10 Norway
13.11 Poland
13.12 Russia
13.13 Spain
13.14 Sweden
13.15 Switzerland
13.16 United Kingdom
13.17 Rest of Europe
14 Middle East and Africa's Cardiovascular Drugs Market
14.1 Introduction
14.2 Egypt
14.3 Israel
14.4 Qatar
14.5 Saudi Arabia
14.6 South Africa
14.7 United Arab Emirates
14.8 Rest of MEA
15 APAC's Cardiovascular Drugs Market
15.1 Introduction
15.2 Australia
15.3 Bangladesh
15.4 China
15.5 India
15.6 Indonesia
15.7 Japan
15.8 Malaysia
15.9 Philippines
15.10 Singapore
15.11 South Korea
15.12 Sri Lanka
15.13 Thailand
15.14 Taiwan
15.15 Rest of Asia-Pacific
16 Competitive Landscape
16.1 Competitive Quadrant
16.2 Market Share Analysis
16.3 Strategic Initiatives
16.3.1 M&A and Investments
16.3.2 Partnerships and Collaborations
16.3.3 Product Developments and Improvements
17 Company Profiles
17.1 Abbott Laboratories
17.2 Amgen, Inc.
17.3 Astellas Pharma, Inc.
17.4 AstraZeneca PLC
17.5 Aurobindo Pharma Ltd.
17.6 Baxter International, Inc.
17.7 Bayer Ag
17.8 Boehringer Ingelheim GmbH
17.9 Bristol-Myers Squibb Co.
17.10 Cipla Ltd.
17.11 Daiichi Sankyo Co., Ltd.
17.12 Eli Lilly and Co.
17.13 F.Hoffman-La Roche Ltd.
17.14 Gilead Science, Inc.
17.15 GlaxoSmithKline PLC
17.16 Johnson & Johnson Service, Inc.
17.17 Lupin Ltd.
17.18 Medicure, Inc.
17.19 Merck & Co, Inc.
17.20 Novartis Ag
17.21 Otsuka Pharmaceutical
17.22 Pfizer, Inc.
17.23 Sanofi SA
17.24 Sun Pharmaceutical Industries Ltd.
17.25 Tadeka Pharmaceutical Co., Ltd.
17.26 United Therapeutics Corp.
18 Appendix
18.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Baxter International, Inc.
  • Bayer Ag
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Co.
  • F.Hoffman-La Roche Ltd.
  • Gilead Science, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Service, Inc.
  • Lupin Ltd.
  • Medicure, Inc.
  • Merck & Co, Inc.
  • Novartis Ag
  • Otsuka Pharmaceutical
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Tadeka Pharmaceutical Co., Ltd.
  • United Therapeutics Corp.

Table Information